In 485 insulin-naive type 2 diabetes patients, icodec plus semaglutide cut HbA1c more and trimmed weight while glargine users gained 3.81 kg, though GI side effects ran higher.
Recap by typeshit. Full story at Endocrinology Advisor.
German researchers made synthetic versions of peptides from axolotl skin mucus, and some slowed the growth of MRSA, the drug-resistant bacteria.
10:45
The nutrition and exercise graduate walks through her food picks for people on retatrutide, aimed at holding onto muscle during weight loss.
Experts say holding on to weight loss after quitting a GLP-1 is possible and walk through the habits they recommend for the transition.
The study of over 87,000 matched patients 65 and up also found 28% fewer liver decompensation events, but no drop in heart attack or stroke and more osteoporosis diagnoses.
The GLP-1/GIP drug hit up to 19% mean weight loss over 48 weeks in a Chinese phase 3, with fewer GI side effects, Regeneron says. US trials are still ahead.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
Loading…